Back to Ovarian Cancer
NCT04065009
NCT04065009
Who may be able to join
Who might be able to join this trial:
- You have been assessed as generally healthy enough for surgery, with none, mild, or moderate pre-existing health conditions (confirm with trial site)
- You are scheduled for upfront surgery to remove as much cancer as possible for suspected advanced-stage ovarian cancer (stage III or IV)
- You are able and willing to sign a consent form agreeing to take part in the trial
Who may not be able to join:
- You have a medical reason why an epidural (an injection for pain relief near the spine) would not be safe for you
- You have a known allergy to any of the medicines used in this trial, including Ropivacaine or Sufentanil (types of pain relief and anaesthetic drugs)
- You have uncontrolled kidney, liver, or heart failure, or uncontrolled heart disease affecting blood supply to the heart
- You have difficulties with speaking, understanding language, or thinking and memory
- Your surgeon decides during the operation that the cancer removal surgery cannot go ahead due to how far the cancer has spread
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Active, Not Recruiting
Phase
Phase 3
Sponsor
Karolinska Institutet
Registry
clinicaltrials_gov
Start date
26 August 2020
Est. completion
10 January 2024
Where this trial is recruiting
🇸🇪 Sweden
Primary endpoints
Time-interval from upfront surgery to adjuvant chemotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.